TLPH vs AQST โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AQST Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aquestive Therapeutics, Inc. Common Stock (AQST) driven by superior Growth & Margin, Momentum & Technical while TLPH counters with relative strength in Valuation, Options & Structure. Fundamentally, TLPH trades at 1.0x Forward P/E with -1474700.0% operating margin (+0.0% YoY revenue) versus AQST at N/M Forward P/E and -114.1% operating margin (-41.0% YoY). In options structure, TLPH sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against AQST sits in BREAKDOWN (40th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TLPH | AQST | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $53.7M | $448.7M | Larger Scale | AQST |
| Trailing P/E Ratio Valuation | 1.0x | N/M | Lower Multiple | TLPH |
| Forward P/E Ratio Valuation | 1.0x | N/M | Lower Multiple | TLPH |
| Revenue Growth (YoY) Growth | +0.0% | -41.0% | Higher Growth | TLPH |
| Operating Margin (TTM) Profitability | -1474700.0% | -114.1% | Higher Margin | AQST |
| Net Profit Margin Profitability | 0.0% | -162.3% | Higher Margin | TLPH |
| Return on Equity (ROE) Capital Efficiency | -143.4% | 0.0% | Higher ROE | AQST |
| 52-Week Range Position Momentum | 20% ($1โ$2) | 22% ($3โ$7) | Stronger Trend | AQST |
| Beta / 30D Volatility Risk Regime | 1.11ฮฒ ยท 58% Vol | 0.87ฮฒ ยท 56% Vol | Lower Realized Risk | AQST |
| Unified Institutional Score Composite Signal | 37.1 / 100 (SELL) | 59.4 / 100 (HOLD) | Higher Composite | AQST |